




2. LIQUID BIOPSY

2.1 OncoProfile Liquid GENERAL 52

2.2 OncoProfile Liquid COLORRECTAL 14

2.3 OncoProfile Liquid MAMA 12

2.4 OncoProfile Liquid LUNG 12





2.1 OncoProfile Liquid GENERAL 52

This test provides relevant results in patients regarding: tumor heterogeneity, detection of treatment-resistant clones, and detection of recurrence earlier than imaging tests.

The general test is capable of evaluating 52 genes with proven clinical utility in cell-free tumor DNA (ctDNA), including key targets recognized by experts (SNVs, InDels, CNVs, and gene fusions).

Hotspot Genes				CNVs	Fusion Genes
AKT1	ERBB3	KIT	SF3B1	CCND1	ALK
ALK	ERG	KRAS	SMAD4	CCND2	BRAF
APC	ESR1	MAP2K1	SMO	CCND3	ERG
AR	ETV1	MAP2K2	TP53	CDK4	ETV1
ARAF	FBXW7	MET		CDK6	FGFR1
BRAF	FGFR1	MTOR		EGFR	FGFR2
CCND1	FGFR2	MYC		ERBB2	FGFR3
CCND2	FGFR3	NRAS		FGFR1	MET
CCND3	FGFR4	NTRK1		FGFR2	NTRK1
CDK4	FLT3	NTRK3		FGFR3	NTRK3
CDK6	GNA11	PDGFRA		MET	RET
CHEK2	GNAQ	PIK3CA		MYC	ROS1
CTNNB1	GNAS	PTEN			
DDR2	HRAS	RAF1			
EGFR	IDH1	RET			
ERBB2	IDH2	ROS1			

- 52 genes
 - >900 Hotspots e Indels
 - 12 CNVs
- Librería única a partir de ADN y ARN
 - Cobertura extendida de TP53
 - MET exon 14 skipping
- 272 amplicons
 - 96 fusions



2.2 Oncoprofile Liquid COLORRECTAL 14

Our test provides relevant results for patients in terms of tumor heterogeneity, detection of treatment-resistant clones, and detection of recurrence earlier than imaging tests.

The test includes 14 genes with proven clinical utility in cell-free tumor DNA (ctDNA) present in blood plasma.

Genes	
<i>AKT1</i>	<i>GNAS</i>
<i>APC</i>	<i>KRAS</i>
<i>BRAF</i>	<i>MAP2K1</i>
<i>CTNNB1</i>	<i>NRAS</i>
<i>EGFR</i>	<i>PIK3CA</i>
<i>ERBB2</i>	<i>SMAD4</i>
<i>FBXW7</i>	<i>TP53</i>

- 14 genes
- 49 amplicons
- 236 Hotspots e Indels



2.3 OncoProfile Liquid MAMA 12

The test evaluates 12 genes with proven clinical utility in cell-free tumor DNA (ctDNA) present in blood plasma.

Our test provides patients with relevant results regarding tumor heterogeneity, detection of treatment-resistant clones, and detection of recurrence earlier than imaging tests.

Genes	
<i>AKT1</i>	<i>FBXW7</i>
<i>CCND1</i>	<i>FGFR1</i>
<i>EGFR</i>	<i>KRAS</i>
<i>ERBB2</i>	<i>PIK3CA</i>
<i>ERBB3</i>	<i>SF3B1</i>
<i>ESR1</i>	<i>TP53</i>

- 12 genes
- 76 amplicons
- >150 hotspots
- CNVs: *CCND1*, *ERBB2*, *FGFR1*
- Amplia cobertura de *TP53*



2.4 OncoProfile Liquid LUNG 12

Our test is capable of evaluating 12 genes with proven clinical utility in cell-free tumor DNA (ctDNA) present in blood plasma.

Our test provides patients with relevant results regarding: tumor heterogeneity, detection of treatment-resistant clones, and detection of recurrence earlier than imaging tests.

Genes		Fusion Genes
ALK	NRAS	ALK
BRAF	PIK3CA	ROS1
EGFR	RET	RET
ERBB2	ROS1	
KRAS	TP53	
MAP2K1		
MET		